AR035745A1 - Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp - Google Patents

Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp

Info

Publication number
AR035745A1
AR035745A1 ARP020100402A ARP020100402A AR035745A1 AR 035745 A1 AR035745 A1 AR 035745A1 AR P020100402 A ARP020100402 A AR P020100402A AR P020100402 A ARP020100402 A AR P020100402A AR 035745 A1 AR035745 A1 AR 035745A1
Authority
AR
Argentina
Prior art keywords
mutation
seq
nos
set forth
polypeptide
Prior art date
Application number
ARP020100402A
Other languages
English (en)
Spanish (es)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR035745A1 publication Critical patent/AR035745A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP020100402A 2001-03-15 2002-02-07 Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp AR035745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
AR035745A1 true AR035745A1 (es) 2004-07-07

Family

ID=25201919

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020100402A AR035745A1 (es) 2001-03-15 2002-02-07 Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp
ARP090101850A AR071888A2 (es) 2001-03-15 2009-05-22 Bacteria pasteurellaceae gram-negativa, una composicion inmunogena, una composicion para vacunas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP090101850A AR071888A2 (es) 2001-03-15 2009-05-22 Bacteria pasteurellaceae gram-negativa, una composicion inmunogena, una composicion para vacunas

Country Status (18)

Country Link
US (2) US6790950B2 (https=)
EP (1) EP1368456B1 (https=)
JP (2) JP2005502315A (https=)
AR (2) AR035745A1 (https=)
AT (1) ATE500316T1 (https=)
AU (1) AU2002240033B2 (https=)
CA (2) CA2438315C (https=)
CY (1) CY1112014T1 (https=)
DE (1) DE60239318D1 (https=)
DK (1) DK1368456T3 (https=)
ES (1) ES2362041T3 (https=)
MX (1) MXPA03008296A (https=)
NZ (1) NZ528208A (https=)
PE (1) PE20021008A1 (https=)
PT (1) PT1368456E (https=)
SI (1) SI1368456T1 (https=)
TW (4) TWI328035B (https=)
WO (1) WO2002075507A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
HK1045856A1 (zh) 1999-04-09 2002-12-13 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2073829B1 (en) * 2006-10-05 2012-06-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Gas57 돌연변이 항원 및 gas57 항체
WO2009137532A1 (en) 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
AU2009266920A1 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising Pasteurella multocida recombinant filamentous hemagglutinin peptides
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
EP3062816B1 (en) * 2013-11-01 2020-08-05 Boehringer Ingelheim Animal Health USA Inc. Attenuated pasteurella multocida vaccines & methods of making & use thereof
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
EP0668779A4 (en) 1992-11-06 1996-08-21 Univ Minnesota Vaccine to protect against pasteurellosis - infection by P.multocida.
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
DE19502584C2 (de) 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
ATE419371T1 (de) * 1996-09-06 2009-01-15 Jensen Peter Ruhdal Verfahren zur verbesserung der herstellung eines erwünschten produktes aus einer zelle
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
HK1045856A1 (zh) 1999-04-09 2002-12-13 法玛西雅厄普约翰美国公司 抗细菌疫苗组合物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AU4204800A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
US20030180330A1 (en) * 2000-04-27 2003-09-25 Meyer Thomas F Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
US20040110268A1 (en) 2004-06-10
SI1368456T1 (sl) 2011-06-30
PE20021008A1 (es) 2002-11-13
CA2852293A1 (en) 2002-09-26
JP2011097938A (ja) 2011-05-19
WO2002075507B1 (en) 2003-12-11
WO2002075507A2 (en) 2002-09-26
TWI335934B (en) 2011-01-11
NZ528208A (en) 2008-04-30
WO2002075507A3 (en) 2003-09-12
ATE500316T1 (de) 2011-03-15
TW201040261A (en) 2010-11-16
EP1368456B1 (en) 2011-03-02
US7476391B2 (en) 2009-01-13
TWI335935B (en) 2011-01-11
AR071888A2 (es) 2010-07-21
PT1368456E (pt) 2011-06-01
CY1112014T1 (el) 2015-11-04
CA2438315A1 (en) 2002-09-26
US20050003512A1 (en) 2005-01-06
TW201040262A (en) 2010-11-16
EP1368456A2 (en) 2003-12-10
MXPA03008296A (es) 2007-05-28
DK1368456T3 (da) 2011-05-23
TWI328035B (en) 2010-08-01
ES2362041T3 (es) 2011-06-27
US6790950B2 (en) 2004-09-14
TW200916577A (en) 2009-04-16
AU2002240033B2 (en) 2007-11-08
DE60239318D1 (de) 2011-04-14
JP2005502315A (ja) 2005-01-27
TWI334884B (en) 2010-12-21
CA2438315C (en) 2014-09-02

Similar Documents

Publication Publication Date Title
AR035745A1 (es) Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp
CN106062203B (zh) 宿主细胞修饰的方法
Morita et al. Cell wall-anchored nuclease of Streptococcus sanguinis contributes to escape from neutrophil extracellular trap-mediated bacteriocidal activity
Choi et al. Enhanced production of recombinant proteins with Corynebacterium glutamicum by deletion of insertion sequences (IS elements)
Gahan et al. The use of listeriolysin to identify in vivo induced genes in the gram‐positive intracellular pathogen Listeria monocytogenes
SA93130462B1 (ar) طوافر mutants مزالة السمية مولدة للمناعة من سم الكوليرا ومن سم غير ثابت حراريا , تحضيرها واستحدامها لتحضير اللقاحات
Shibata et al. Identification and characterization of an autolysin-encoding gene of Streptococcus mutans
Hartmann et al. The glycosylated cell surface protein Rpf2, containing a resuscitation-promoting factor motif, is involved in intercellular communication of Corynebacterium glutamicum
CN107109422A (zh) 使用由两个载体表达的Cas9蛋白质调节基因表达的方法
CN104837984A (zh) 宿主细胞修饰方法
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
EP3262061B1 (en) Peptides for facilitating secretion and uses thereof
Salvetti et al. FlhF, a signal recognition particle-like GTPase, is involved in the regulation of flagellar arrangement, motility behaviour and protein secretion in Bacillus cereus
JP6161190B2 (ja) 耐熱性ケラチナーゼ酵素、その製造方法、およびそれをコードするdna
JP2005502315A5 (https=)
Filiatrault et al. Construction and characterization of Haemophilus ducreyi lipooligosaccharide (LOS) mutants defective in expression of heptosyltransferase III and β1, 4-glucosyltransferase: identification of LOS glycoforms containing lactosamine repeats
Silakowski et al. fbfB, a gene encoding a putative galactose oxidase, is involved in Stigmatella aurantiaca fruiting body formation
Bannam et al. Mutagenesis of active-site histidines of Listeria monocytogenes phosphatidylinositol-specific phospholipase C: effects on enzyme activity and biological function
Bereswill et al. The ferric uptake regulator (Fur) homologue of Helicobacter pylori: functional analysis of the coding gene and controlled production of the recombinant protein in Escherichia coli
CN114616348A (zh) 皮革改性剂
HUT53154A (en) Process for producing protease-defective gram-positive bacteria and utilizing them as host-organizmus for producing recombinant products
JP2001510037A (ja) グラム陽性微生物からのプロテアーゼ
US20160304845A1 (en) New dna cleavage enzyme
JP2005517435A (ja) 新規の真菌リパーゼ
Bereswill et al. Hemolytic properties and riboflavin synthesis of Helicobacter pylori: cloning and functional characterization of the rib A gene encoding GTP-cyclohydrolase II that confers hemolytic activity to Escherichia coli

Legal Events

Date Code Title Description
FC Refusal